Study identification

PURI

https://redirect.ema.europa.eu/resource/32900

EU PAS number

EUPAS32899

Study ID

32900

Official title and acronym

Severe Asthma Super-Responders Delphi Exercise

DARWIN EU® study

No

Study countries

Argentina
Australia
Belgium
Bulgaria
Canada
Colombia
Denmark
Estonia
Finland
France
Germany
Greece
Iceland
India
Italy
Kuwait
Mexico
Netherlands
New Zealand
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
Thailand
United Arab Emirates
United Kingdom
United States

Study description

This study aims to survey health care professionals in multiple countries to define a consensus-based definition of a severe asthma ‘super-responder’. Primary objectives of this study are to follow a Delphi process to define an international consensus-based definition of a ‘super-responder’, targeting health care professionals in multiple countries who treat severe asthma. The Delphi process will comprise of two or three iterative rounds of electronic surveys to gather anonymised opinions on the definition of a super-responder. De-identified data will be collected after each round and summary statistics completed to identify if consensus has been reached for each topic.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

John Upham

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

Observational Pragmatic Research Institute (OPI)
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable